Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-09-10 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公开发行可转债申请文件反馈意见回复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding their response to feedback from the China Securities Regulatory Commission (CSRC) on their application for a public issuance of convertible bonds. It mentions the submission of feedback reply documents and the need for CSRC approval, highlighting the uncertainty of approval and investment risks. The content focuses on capital raising activities and regulatory feedback related to financing. The document length is short (605 characters) and it is an announcement rather than a full report or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP).
2019-09-10 Chinese
关于昆药集团股份有限公司公开发行可转债申请文件反馈意见的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to feedback from the China Securities Regulatory Commission regarding the application for public issuance of convertible bonds by Kunming Pharmaceutical Group Co., Ltd. It includes extensive discussion on business operations, regulatory compliance, and specific issues related to the bond issuance process. The content focuses on regulatory feedback, compliance with issuance rules, and detailed explanations related to the bond issuance application rather than financial results or earnings. The document is not an annual or interim report, earnings release, or audit report. It is not a call transcript, nor a management or investor presentation. It is a regulatory filing responding to a regulatory authority's feedback on a financing activity (convertible bond issuance). Given the nature of the document as a formal reply to regulatory feedback on a financing application, it fits best under Regulatory Filings (RNS).
2019-09-10 Chinese
关于公司产品入选国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the inclusion and adjustment of its products in the National Medical Insurance Catalog. It details product classifications, descriptions, and revenue data related to these products. The document is relatively short (2155 characters) and serves as an official announcement about product status changes in a government insurance catalog, rather than a financial report or detailed regulatory filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it is the announcement itself. The content fits best under a general regulatory announcement category that does not fit other specific categories.
2019-08-21 Chinese
关于收到《中国证监会行政许可项目审查一次反馈意见通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding receipt of a feedback notice from the China Securities Regulatory Commission (CSRC) about their administrative license application for issuing convertible bonds. It states the company will respond within 30 days and that approval is uncertain. The document is short (588 characters) and serves as a regulatory update on the status of a financing approval process, not a financial report or detailed filing. It does not contain financial statements or detailed financial data. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and compliance update.
2019-08-19 Chinese
关于昆药集团子公司昆明贝克诺顿制药有限公司收购“贝克诺顿（浙江）制药有限公司”30%股权的补充公告
Capital/Financing Update Classification · 95% confidence The document is a supplementary announcement regarding the acquisition of a 30% equity stake in a subsidiary company by Kunming Beckenoton Pharmaceutical Co., Ltd., a subsidiary of Kunming Pharmaceutical Group Co., Ltd. It provides detailed information about the transaction counterparties, their backgrounds, financial data of related companies, valuation adjustments, and risk disclosures. The document is an announcement supplementing a previous acquisition announcement, focusing on transaction details and financial information related to the acquisition. It does not contain a full financial report, audit report, or regulatory certification, nor is it a voting result or management change announcement. It is a capital transaction update related to share acquisition and equity changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3515 characters, which is consistent with an announcement rather than a full report.
2019-08-15 Chinese
九届八次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kunming Pharmaceutical Corporation regarding the review and approval of the company's 2019 semi-annual report and related matters. It includes the Supervisory Board's audit opinions on the 2019 semi-annual report, compliance with laws and regulations, and approval of changes in accounting standards. The document is not the semi-annual report itself but a formal announcement of the Supervisory Board's review and approval of that report. The document length is short (1232 characters), and it primarily contains meeting resolutions and audit opinions rather than detailed financial statements or substantive financial data. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement related to regulatory compliance and supervisory board resolutions, not the full interim report (IR) itself.
2019-08-14 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.